Over a three-week period, the officials traveled throughout the U.S. to gain a better understanding of the current practices of food and drug safety as China is looking to improve their regulatory oversight and standards.
During the visit on Oct. 29, BioScreen conducted a presentation on how the U.S. FDA inspects and regulates laboratories and industries in the U.S. and provided a comprehensive tour of the BioScreen Laboratories.
In addition to educating the officials on U.S. general practices, BioScreen management also learned a great deal regarding the regulation of drugs and cosmetics in China and gained invaluable insight into China’s current and future regulatory goals.
BioScreen was among the many prestigious organizations that the Chinese officials visited—and was the only privately held contract laboratory. Other stops included Pfizer in New Jersey, the California Food and Drug branch in Berkeley, CA, and the FDA headquarters in Washington D.C.
Some of the notable officials were Mr. Zhang Juan, division chief of the Chongqing Food and Drug Administration, Ms. Yang Weidong, director general, and Mr. Fu Jiajun, deputy director general.